DAPK1 Antibody

What are the primary applications for DAPK1 antibodies in research?

DAPK1 antibodies can be utilized in multiple experimental applications, with varying recommended dilutions for optimal results:

These applications allow researchers to detect endogenous DAPK1 expression, localization, and protein-protein interactions in various experimental models . When selecting a DAPK1 antibody, researchers should consider the specific application requirements and validate the antibody performance in their experimental system.

What is the optimal specimen preparation protocol for DAPK1 immunohistochemistry?

For successful immunohistochemical detection of DAPK1:

• Fix tissue samples in 10% neutral buffered formalin for 24-48 hours

• Process and embed in paraffin following standard protocols

• Section tissues at 4-6 μm thickness

• Perform antigen retrieval using TE buffer pH 9.0 (preferred method)

• Alternatively, citrate buffer pH 6.0 can be used if TE buffer yields suboptimal results

• Apply DAPK1 antibody at dilutions between 1:100-1:800 depending on the specific antibody

• Incubate according to the manufacturer's recommended protocol (typically overnight at 4°C)

• Use appropriate detection systems compatible with the host species of the primary antibody

Positive IHC signals have been detected in human small intestine tissue, breast cancer tissue, placenta tissue, stomach cancer tissue, and various mouse and rat tissues . Proper antigen retrieval is critical for exposing epitopes that may be masked during fixation.

How should DAPK1 antibodies be stored to maintain optimal reactivity?

To ensure long-term stability and performance of DAPK1 antibodies:

• Store concentrated antibody solutions at -20°C for long-term storage

• Most DAPK1 antibodies remain stable for one year after shipment when properly stored

• For polyclonal antibodies supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, aliquoting is generally unnecessary for -20°C storage

• For working solutions, store at 4°C for up to two weeks

• Avoid repeated freeze-thaw cycles by preparing appropriately sized aliquots

• Briefly centrifuge antibody vials prior to opening to collect solution at the bottom

• Some formulations with 0.1% BSA may have specific storage requirements - check product documentation

Following proper storage protocols ensures maintained antibody performance and extends shelf life for ongoing research applications.

What cell lines serve as positive controls for DAPK1 antibody validation?

Several established cell lines express detectable levels of endogenous DAPK1 and can serve as appropriate positive controls:

For tissue controls, human small intestine, breast cancer, and placenta tissues have demonstrated reliable DAPK1 immunoreactivity . When validating a new DAPK1 antibody, researchers should include both positive and negative controls to confirm specificity and performance.

How can researchers effectively distinguish between phosphorylated and non-phosphorylated forms of DAPK1?

Distinguishing between phosphorylated and non-phosphorylated DAPK1 is crucial for understanding its regulation and activation state:

• Use phospho-specific antibodies that target key regulatory sites, particularly Ser308, which is the major auto-phosphorylation site that negatively regulates DAPK1 activity

• Implement a dual immunoblotting approach:

  • Probe one membrane with phospho-specific DAPK1 antibody

  • Probe a parallel membrane with pan-DAPK1 antibody

  • Calculate the phospho/total DAPK1 ratio to assess activation status

• Include appropriate controls:

  • Positive control: Untreated cells typically show basal phosphorylation

  • Negative control: DAPK1 knockout cells or tissues

  • Treatment control: Cells treated with phosphatase to remove phosphorylation

• For immunofluorescence applications, use sequential staining with phospho-specific and total DAPK1 antibodies with distinct fluorophores to visualize co-localization

Research has shown that DAPK1 phosphorylation status, particularly at Ser308, is critical for its function in neuronal cell death and Alzheimer's disease pathology . Monitoring phosphorylation state provides insights into DAPK1 activation in response to cellular stressors.

What experimental approaches can verify DAPK1-substrate interactions in neuronal models?

To verify and characterize DAPK1-substrate interactions in neuronal models:

• Co-immunoprecipitation (Co-IP) analysis:

  • Immunoprecipitate DAPK1 from neuronal lysates using specific antibodies

  • Analyze precipitated complexes for known or suspected substrates

  • Perform reverse Co-IP to confirm interaction bidirectionally

  • Example: DAPK1 has been shown to interact with NDRG2 in 293T or SH-SY5Y cells and in mouse whole-brain lysates

• In vitro kinase assays:

  • Express and purify recombinant DAPK1 and potential substrates

  • Perform kinase reactions with γ-32P-ATP or ATP and analyze by autoradiography or phospho-specific antibodies

  • Include kinase-dead DAPK1 mutants as negative controls

  • Analysis has confirmed DAPK1 phosphorylation of substrates like NDRG2 at Ser350

• Proximity ligation assay (PLA):

  • Utilize specific antibodies against DAPK1 and potential substrates

  • PLA signal indicates protein-protein proximity (<40 nm)

  • Quantitative analysis of interaction intensity in different cellular compartments

• Functional validation approaches:

  • Overexpress wild-type DAPK1 versus kinase-dead mutants

  • Assess substrate phosphorylation and downstream effects

  • Use DAPK1 inhibitors to confirm kinase-dependent effects

  • Implement DAPK1 knockdown using shRNA to validate specificity

Studies have demonstrated that DAPK1-substrate interactions are critical in neuronal pathways related to Alzheimer's disease, where phosphorylation of substrates like NDRG2 contributes to neuronal cell death mechanisms .

How do different DAPK1 antibody clones perform in detecting its expression in neurodegenerative disease models?

The performance of DAPK1 antibodies in neurodegenerative disease models varies depending on epitope accessibility and specificity:

• Epitope considerations:

  • N-terminal antibodies (targeting residues near the kinase domain): Effective for detecting full-length DAPK1 but may miss splice variants

  • C-terminal antibodies (e.g., those targeting residues 1360-1389): Better for detecting multiple DAPK1 isoforms but may show reduced sensitivity in some applications

  • Death domain-targeting antibodies: Useful for studying protein-protein interactions in death signaling pathways

• Performance comparison in AD models:

  • Polyclonal antibodies have successfully detected increased DAPK1 expression in hippocampi of AD patients compared to age-matched controls

  • Monoclonal antibodies provide more consistent results across experiments but may have more restricted epitope recognition

  • Phospho-specific antibodies have demonstrated increased phosphorylated NDRG2 Ser350 and DAPK1 levels in human AD brain samples

• Technical considerations:

  • IHC applications in AD brain tissues benefit from extended antigen retrieval procedures (>20 minutes)

  • For detection of DAPK1 in mouse models of neurodegeneration, antibodies with confirmed mouse reactivity are essential

  • Western blot detection of DAPK1 in brain lysates typically reveals bands at 140-160 kDa

Research has shown that DAPK1 expression is significantly upregulated in hippocampi of AD patients and contributes to tau protein accumulation and phosphorylation, and amyloidogenic APP processing . Selecting the appropriate antibody is crucial for accurate characterization of DAPK1's role in disease models.

What strategies can resolve contradictory DAPK1 expression data across different experimental models?

When facing contradictory DAPK1 expression data across different experimental models, consider these methodological approaches:

• Antibody validation strategy:

  • Test multiple antibodies targeting different epitopes of DAPK1

  • Include DAPK1 knockout/knockdown samples as negative controls

  • Verify antibody specificity using Western blot in conjunction with mass spectrometry

  • Preabsorb antibodies with immunizing peptides to confirm specificity

  • Example: The DAPK1 monoclonal antibody 67815-1-Ig has shown consistent results across multiple cell lines

• Technical optimization approach:

  • Standardize sample preparation protocols across experiments

  • Optimize protein extraction methods for different tissue types

  • Adjust antigen retrieval methods for IHC (compare citrate buffer pH 6.0 vs. TE buffer pH 9.0)

  • Validate RNA expression with protein expression using RT-qPCR and Western blot

  • Control for post-translational modifications that may affect antibody binding

• Contextual analysis framework:

  • Consider cellular stress conditions that affect DAPK1 expression

  • Account for variability in DAPK1 expression during disease progression

  • Assess expression in specific cellular compartments using fractionation

  • Control for age, sex, and genetic background in animal models

  • Studies have shown sex-specific differences in DAPK1-related gene expression patterns in brain regions

• Integrated multi-omics approach:

  • Combine antibody-based detection with RNA-seq analysis

  • Use phospho-proteomics to map DAPK1 activation networks

  • Correlate DAPK1 expression with functional outcomes

  • Researchers have identified significantly altered genes in different brain regions of male and female DAPK1-KO mice compared to wild-type mice

By implementing these strategies, researchers can resolve contradictory data and develop a more cohesive understanding of DAPK1 expression patterns across experimental models.

How can DAPK1 antibodies be effectively employed to study its role in inflammatory pathways related to arterial aneurysm?

To investigate DAPK1's role in inflammatory pathways related to arterial aneurysm:

• Sequential immunohistochemical analysis:

  • Perform dual staining with DAPK1 antibodies and inflammatory markers (TNF-α, IL-6, IL-1β)

  • Quantify co-localization in arterial tissue sections

  • Compare DAPK1 expression patterns between healthy and aneurysmal tissues

  • Research has shown increased DAPK1 mRNA expression in patients with arterial aneurysm

• In vitro inflammatory model approach:

  • Treat vascular smooth muscle cells with inflammatory stimuli (TNF-α, IL-1β)

  • Assess DAPK1 expression and phosphorylation status

  • Implement DAPK1 knockdown to evaluate effects on inflammatory cytokine production

  • Studies have demonstrated that knockout of DAPK1 reduces inflammation in arterial aneurysm models

• Pathway analysis methodology:

  • Use DAPK1 antibodies to immunoprecipitate protein complexes

  • Analyze binding partners using mass spectrometry

  • Map DAPK1 interactions with Beclin1/NLRP3 pathway components

  • Research has identified Beclin1/NLRP3 signal pathway as a critical downstream effector of DAPK1 by ATP production in arterial aneurysm

• Translational research protocol:

  • Collect human arterial aneurysm samples

  • Perform Western blot analysis of DAPK1 expression

  • Correlate with clinical parameters and inflammatory markers

  • Implement a standardized protocol using antibody dilution of 1:1000 for consistent results

Research has shown that DAPK1 may function as a potential biomarker for arterial aneurysm in clinical treatment and activated inflammation levels in arterial aneurysm . Studies in knockout models have demonstrated that deletion of DAPK1 reduced incidence of AngII-induced abdominal aortic aneurysm (AAA) and inhibited inflammatory cytokine production.

What are the most effective protocols for reducing background and non-specific binding with DAPK1 antibodies?

To minimize background and non-specific binding when working with DAPK1 antibodies:

• Optimized blocking strategy:

  • Use 5% BSA in TBS-T for Western blotting applications

  • For IHC/IF, implement species-matched normal serum (5-10%) with 0.3% Triton X-100

  • Include 0.05-0.1% Tween-20 in washing buffers

  • Extend blocking time to 1-2 hours at room temperature

• Antibody dilution optimization:

  • Titrate antibody concentrations using a dilution series

  • For Western blot, test dilutions between 1:500-1:4000

  • For IHC, evaluate dilutions between 1:100-1:800

  • For IF/ICC, determine optimal dilution between 1:50-1:1600

• Incubation condition refinement:

  • For primary antibodies, incubate overnight at 4°C rather than at room temperature

  • For secondary antibodies, limit incubation to 30-60 minutes at room temperature

  • Perform all incubations with gentle agitation to ensure even distribution

• Pre-adsorption technique:

  • When possible, pre-adsorb antibodies with tissue/cell lysates from species different from the target

  • For polyclonal antibodies, consider pre-adsorption with immunizing peptide competition assays

  • Implement proper controls with pre-immune serum when available

Following these protocols will help minimize background and increase signal specificity when using DAPK1 antibodies across different experimental applications.

What experimental design would best elucidate DAPK1's phosphorylation targets in neuronal cell death models?

To comprehensively identify and characterize DAPK1's phosphorylation targets in neuronal cell death models:

• Phospho-proteomic screening approach:

  • Compare phospho-proteomes between wild-type and DAPK1-KO primary neurons under stress conditions

  • Use SILAC or TMT labeling for quantitative analysis

  • Enrich phosphopeptides using TiO2 or IMAC techniques

  • Apply stringent criteria identifying consensus DAPK1 phosphorylation motifs (RxxS/T)

  • This approach identified NDRG2 as a novel DAPK1 substrate

• Candidate substrate validation workflow:

  • Express recombinant substrate in the presence of wild-type or kinase-dead DAPK1

  • Perform in vitro kinase assays with purified components

  • Analyze phosphorylation by mass spectrometry to identify exact sites

  • Generate phospho-site specific antibodies for key substrates

  • Create phospho-mimetic and phospho-null mutants to assess functional effects

  • Studies confirmed DAPK1 phosphorylates NDRG2 on Ser350

• Functional consequence analysis:

  • Evaluate cell death parameters in neuronal models expressing wild-type versus phospho-mutant substrates

  • Assess caspase activation, PARP cleavage, and apoptotic morphology

  • Utilize live-cell imaging with fluorescent reporters of cell death

  • Research demonstrated that NDRG2-mediated cell death by DAPK1 required caspase-dependent PARP cleavage

• In vivo validation experimental design:

  • Develop phospho-specific antibodies against identified targets

  • Compare phosphorylation patterns in various neurodegeneration models

  • Analyze human patient samples for phosphorylation signatures

  • Studies revealed increased levels of phosphorylated NDRG2 Ser350 and DAPK1 in human AD brain samples

This experimental framework allows for comprehensive identification and functional validation of DAPK1 phosphorylation targets in neuronal cell death models, providing insights into disease mechanisms.

How can researchers accurately quantify DAPK1 expression levels across different brain regions in neurodegeneration studies?

For accurate quantification of DAPK1 expression across brain regions in neurodegeneration studies:

• Region-specific sampling protocol:

  • Use stereotaxic coordinates for precise dissection of brain regions

  • Process samples consistently using standardized protein extraction methods

  • Normalize protein loading using multiple housekeeping controls (β-actin, GAPDH)

  • Include region-specific markers to confirm anatomical precision

  • Studies have shown differential DAPK1 expression across cerebral cortex, hippocampus, brain stem, and cerebellum

• Quantitative Western blot methodology:

  • Implement fluorescent secondary antibodies for broader linear detection range

  • Use internal standard curves on each blot for absolute quantification

  • Normalize DAPK1 signal to total protein measured by Ponceau S or Stain-Free technology

  • Process multiple biological replicates (n≥5) to account for individual variation

  • DAPK1 is typically detected as 140-160 kDa bands on Western blots

• Immunohistochemical quantification approach:

  • Apply stereological methods for unbiased cell counting

  • Use automated image analysis software with consistent thresholding parameters

  • Implement tile scanning for whole-region analysis rather than representative fields

  • Account for background using isotype controls and DAPK1-KO tissues

  • Calculate DAPK1-positive cell density per unit area across regions

• Multi-modal validation strategy:

  • Correlate protein levels (Western blot) with mRNA expression (RT-qPCR or RNA-seq)

  • Complement with in situ hybridization for cellular resolution

  • Validate antibody specificity in each brain region using DAPK1-KO controls

  • Research has identified significantly altered gene expression in different brain regions of DAPK1-KO mice

This comprehensive approach ensures accurate quantification of DAPK1 expression across brain regions, facilitating meaningful comparisons in neurodegeneration studies.

How can DAPK1 antibodies be employed to investigate its role in autophagy regulation during neurodegeneration?

To investigate DAPK1's role in autophagy regulation during neurodegeneration:

• Co-localization analysis protocol:

  • Perform dual immunofluorescence with DAPK1 and autophagy markers (LC3, p62, Beclin1)

  • Use super-resolution microscopy for precise spatial relationships

  • Quantify co-localization coefficients under basal and stress conditions

  • Implement 3D reconstruction for volumetric analysis

  • Research has identified DAPK1 phosphorylation of Beclin1 as a key regulatory mechanism

• Autophagy flux assessment methodology:

  • Compare autophagosome formation in wild-type versus DAPK1-KO neurons using LC3-II/LC3-I ratios

  • Utilize tandem fluorescent-tagged LC3 (mRFP-GFP-LC3) to distinguish autophagosomes from autolysosomes

  • Measure flux with lysosomal inhibitors (Bafilomycin A1, Chloroquine)

  • Correlate with DAPK1 activity using phospho-specific antibodies

  • DAPK1 has been shown to phosphorylate Beclin1, reducing its interaction with BCL2 and promoting autophagy induction

• DAPK1-Beclin1 interaction study design:

  • Immunoprecipitate DAPK1 complexes from neuronal lysates under various conditions

  • Probe for Beclin1 and assess phosphorylation status

  • Implement proximity ligation assays for in situ interaction detection

  • Compare interaction patterns across various neurodegenerative disease models

  • Research has shown that DAPK1 phosphorylates Beclin1, disrupting its interaction with Bcl-2

• Therapeutic modulation experimental framework:

  • Apply DAPK1 inhibitors to neuronal cultures undergoing stress

  • Assess changes in autophagy markers and flux

  • Evaluate neuroprotective effects through viability assays

  • Correlate with functional outcomes in animal models

  • Studies have demonstrated that inhibition of DAPK1 using inhibitors significantly decreased neuronal cell death

This methodological framework enables comprehensive investigation of DAPK1's role in autophagy regulation during neurodegeneration, potentially identifying new therapeutic targets.

What are the methodological considerations when using DAPK1 antibodies to study sex-specific differences in neurodegenerative disorders?

When investigating sex-specific differences in DAPK1 expression and function in neurodegenerative disorders:

• Experimental design considerations:

  • Include balanced cohorts of male and female subjects/animals

  • Stratify analyses by sex prior to pooling data

  • Account for hormonal status and cycle phase in female subjects

  • Include appropriate sex-matched controls for all experiments

  • Studies have shown significantly altered genes in the cerebral cortex, hippocampus, brain stem, and cerebellum of both male and female DAPK1-KO mice compared to wild-type mice, with distinct patterns

• Antibody validation for sex-specific studies:

  • Verify antibody performance in both male and female tissues independently

  • Establish separate normalization controls for each sex

  • Confirm epitope accessibility is not affected by sex-specific post-translational modifications

  • Include DAPK1-KO controls from both sexes when available

• Hormonal influence assessment protocol:

  • Evaluate DAPK1 expression across estrous cycle stages

  • Test effects of gonadectomy on DAPK1 levels and localization

  • Assess impact of hormone replacement on DAPK1 function

  • Analyze DAPK1-dependent signaling pathways for sex-specific regulation

• Integrated multi-omics approach:

  • Combine antibody-based detection with sex-stratified transcriptomics

  • Implement phospho-proteomics to identify sex-specific phosphorylation targets

  • Correlate findings with functional and behavioral outcomes

  • Analyze human patient samples with strict sex-matching criteria

  • Research has demonstrated sex-specific transcriptional profiles in DAPK1-KO mice

These methodological considerations ensure robust analysis of sex-specific differences in DAPK1 expression and function in neurodegenerative disorders, potentially revealing sex-specific therapeutic targets.

What criteria should researchers use to select the optimal DAPK1 antibody for specific experimental applications?

When selecting the optimal DAPK1 antibody for specific experimental applications, researchers should consider:

• Application-specific performance criteria:

• Target specificity considerations:

  • Confirm reactivity with species of interest (human, mouse, rat)

  • Verify isoform specificity if studying particular DAPK1 variants

  • For phospho-specific applications, ensure antibody recognizes only the phosphorylated form

  • Review published validation data including knockout/knockdown controls

  • Check cross-reactivity with other DAPK family members (DAPK2, DAPK3)

• Technical characteristics assessment:

  • Antibody class (monoclonal vs. polyclonal) based on experimental needs

  • Host species compatibility with existing secondary antibodies and other primaries

  • Clonality (monoclonal for consistency, polyclonal for enhanced detection)

  • Immunogen location (N-terminal, kinase domain, death domain, C-terminal)

  • Purification method (affinity-purified antibodies typically show higher specificity)

• Validation evidence evaluation:

  • Review published literature using the antibody for similar applications

  • Assess validation data including Western blot images showing single bands

  • Check for validated positive control cell lines/tissues

  • Review knockout/knockdown validation data when available

  • Consider antibodies with demonstrated performance in specific disease models relevant to your research

Careful selection based on these criteria will ensure optimal performance in specific experimental applications and increase research reliability.

What validation procedures should researchers implement before using a new DAPK1 antibody lot?

Before implementing a new DAPK1 antibody lot in research protocols, thorough validation is essential:

• Basic characterization protocol:

  • Perform side-by-side comparison with previous lot using the same samples

  • Verify recognition of the expected molecular weight band (140-160 kDa) by Western blot

  • Confirm signal intensity at standard dilutions (e.g., 1:1000 for WB, 1:200 for IHC)

  • Assess background levels and non-specific binding

  • Determine lot-specific optimal dilutions for each application

• Specificity validation workflow:

  • Test antibody on samples with known DAPK1 expression (e.g., A549, HeLa cells)

  • Include negative controls (DAPK1 knockout/knockdown when available)

  • Perform peptide competition assay using the immunizing peptide

  • Verify absence of signal in tissues/cells not expressing DAPK1

  • For phospho-specific antibodies, treat samples with phosphatases as negative controls

• Application-specific validation:

  • For WB: Confirm single band at expected molecular weight, assess linearity of detection

  • For IHC/IF: Verify cellular localization patterns, compare with literature reports

  • For IP: Confirm successful pull-down of DAPK1 by Western blot

  • For multi-color IF: Test for cross-reactivity with other primary/secondary antibodies

  • Various cell lines have been validated for different applications with DAPK1 antibodies

• Functional validation approach:

  • Confirm antibody detection of changes in DAPK1 expression or phosphorylation under known regulatory conditions

  • Verify detection of DAPK1 in its active versus inactive conformations

  • For detecting protein-protein interactions, ensure antibody does not interfere with binding regions

  • Test ability to neutralize DAPK1 function in functional assays when relevant

Implementing this comprehensive validation protocol ensures reliability and reproducibility when using new DAPK1 antibody lots in research applications.

How should researchers interpret contradictory results between DAPK1 mRNA expression and protein levels in disease models?

When encountering discrepancies between DAPK1 mRNA and protein levels in disease models:

• Post-transcriptional regulation assessment:

  • Evaluate microRNA targeting DAPK1 mRNA (e.g., miR-103, miR-107)

  • Analyze mRNA stability through actinomycin D chase experiments

  • Assess translational efficiency using polysome profiling

  • Investigate RNA binding proteins that may regulate DAPK1 mRNA

• Post-translational modification analysis:

  • Examine DAPK1 protein stability through cycloheximide chase assays

  • Assess ubiquitination status and proteasomal degradation rates

  • Investigate phosphorylation-dependent stability mechanisms

  • Consider other modifications (acetylation, SUMOylation) that may affect antibody recognition

  • Research has demonstrated that phosphorylation regulates DAPK1 stability and activity

• Technical artifact evaluation:

  • Compare extraction methods optimized for protein versus RNA

  • Validate antibody specificity for detecting modified forms of DAPK1

  • Analyze regional and cellular heterogeneity that may be averaged in bulk analyses

  • Consider temporal dynamics where mRNA changes may precede protein changes

  • Different antibodies may detect distinct epitopes affected by post-translational modifications

• Integrated analysis framework:

  • Implement time-course studies to capture dynamic relationships

  • Utilize single-cell approaches to address cellular heterogeneity

  • Apply computational models incorporating post-transcriptional and post-translational regulation

  • Consider functional readouts (kinase activity assays) rather than absolute levels

  • Studies in neurodegenerative diseases have shown complex regulation of DAPK1 at multiple levels

This systematic approach helps researchers interpret discrepancies between DAPK1 mRNA and protein levels, revealing important regulatory mechanisms that may be disease-relevant.

What methodological approaches can distinguish between DAPK1 family members (DAPK1, DAPK2, DAPK3) in experimental samples?

To accurately distinguish between DAPK1 family members in experimental samples:

• Antibody-based discrimination strategy:

  • Select antibodies targeting non-conserved regions between family members

  • Verify specificity using overexpression systems for each family member

  • Implement Western blot analysis to distinguish based on molecular weight differences:

    • DAPK1: 140-160 kDa

    • DAPK2 (DRP-1): ~42 kDa

    • DAPK3 (ZIPK): ~55 kDa

  • Confirm differential tissue expression patterns as additional validation

• Genetic manipulation approach:

  • Employ specific siRNA/shRNA targeting unique regions of each family member

  • Validate knockdown specificity using qPCR with primers spanning unique regions

  • Utilize CRISPR/Cas9 knockout models with family member-specific guide RNAs

  • Perform rescue experiments with constructs resistant to the specific knockdown

• Mass spectrometry-based identification:

  • Identify family member-specific peptides through sequence analysis

  • Perform immunoprecipitation followed by mass spectrometry

  • Develop targeted MRM (multiple reaction monitoring) assays for specific peptides

  • Quantify relative abundance of each family member in complex samples

• Activity-based profiling:

  • Utilize substrate specificity differences between family members

  • Develop family member-selective inhibitors as analytical tools

  • Perform in vitro kinase assays with recombinant proteins

  • DAPK1 has been shown to phosphorylate specific substrates like NDRG2, which can serve as discriminating markers